For example, several androgen receptor (AR) antagonists—including drospirenone, dienogest, and enzacamene—were identified and listed (Figure 4, Appendix A Table A2), consistent with approach to counteract the upregulated AR expression observed in non-responders in the ESCC cohort. The gene discussed is AR; the disease is esophageal squamous cell carcinoma.